Cytek Biosciences is set to report its quarterly earnings on Tuesday, November 5th. Analysts expect a modest EPS of $0.00, but investors will be looking for signs of exceeding estimates and strong guidance. This earnings release will be crucial for shareholders, especially after the company missed EPS in the previous quarter. This analysis delves into key factors driving Cytek Biosciences’s performance and provides insights from analyst expectations and peer comparisons.